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Use of non-steroidal anti-inflammatory drugs (NSAIDs) is
associated in several large epidemiologic studies with a
lower risk of epithelial cancers including breast though no
randomized, placebo controlled phase III studies have
been conducted to date. NSAID use was associated with a
significantly lower risk of breast cancer among partici-
pants in a multiethnic cohort, though the nearly 50%
reduction in risk was limited to women with estrogen
receptor positive tumors; an observation previously
reported by Terry et al., and supported by Gierach et al.,
and findings of Harris et al for cyclooxygenase-2 (COX-2)
inhibitors. These findings in epidemiologic studies are
supported by work in human mammary tissues and cell
culture where overexpression of COX-2, one of two
cyclooxygenase targets of NSAIDs, acts as an early event in
the transition of normal breast cells to malignancy. Fur-
ther, COX-2-associated prostaglandin E2 (PGE2) produc-
tion has been shown to increase aromatase activity in
mammary epithelial cells possibly explaining the
observed benefit of NSAID use in hormone receptor posi-
tive disease and the recent observation of lower circulating
estradiol levels among regular users of NSAIDs. Thus,
there exists sufficient rationale for the use of NSAIDs for
the prevention of breast cancer.
While the best studied target of NSAIDs is the COX isoen-
zymes, the anti-tumor activities of each of the NSAID
agents via 'non COX' pathways remains unknown. Sulin-
dac, a non selective NSAID with well recognized COX-
independent induction of apoptosis has remained a
strong candidate for chemoprevention largely because of
its broader anti-tumor activity. Growth differentiation fac-
tor 15 (GDF-15), a potent proapoptotic molecule in the
TGF- superfamily and potential tumor suppressor is
upregulated by several NSAIDS independent of its activity
as a COX inhibitor. Sulindac sulfone, a metabolite of
sulindac and a COX-independent mediator of apoptosis,
has been shown to be a potent inducer of GDF-15 at phar-
macologically relevant doses whereas Celecoxib, a COX-2
specific inhibitor, has low GDF-15 induction potency
even at toxic doses. Other NSAIDs such as aspirin and
indomethacin as well as a number of candidate dietary
chemopreventives including resveratrol, indole-3-carbi-
nol, 3,3' Diindolylmethane (DIM), and lycopene as well
as the PPAR agonists troglitazone, and 15-deoxy-12,14-
prostaglandin J2 all show potent induction of GDF-15
leading to the suggestion that GDF-15 might serve as a
complementary molecular target to COX-2 for cancer che-
moprevention and serve as a surrogate biomarker of
apoptotic response.
To better understand the effect of NSAIDs in the breast, we
conducted a phase 1b dose study using sulindac as a rep-
resentative drug of the non selective NSAIDs with known
activity to induce GDF-15 and inhibit COX-2. To assess
sulindac and its metabolites and their effects on a stable
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COX-2 derived prostaglandins 13,14-dihydro-15-keto
prostaglandin A2 [PGEM], and the NSAID inducible
growth differentiation factor (GDF-15) in nipple aspirate
fluid (NAF), we randomized 30 women at increased risk
for breast cancer to 150 mg once daily or twice daily sulin-
dac for 6 weeks. Sulindac and sulfide were detectable in
57.7% of NAF samples with sulfone detectable in 11.6%.
Sulindac was associated in a dose independent manner
with a nonsignificant decrease in NAF PGEM levels (p =
0.1). Serum levels of sulindac, but not NAF sulindac, were
correlated with a decrease in NAF PGEM levels (p = 0.03).
GDF-15, showed a borderline significant trend towards
higher levels in NAF with 300 mg daily sulindac (p =
0.07). This study suggests that COX inhibition in the
breast may be achieved at 150 mg sulindac once daily
while a higher daily dose is needed to exhibit activities via
COX independent pathways. The study also suggests that
NAF levels of PGEM and GDF-15 could be considered as
drug effect biomarkers for future early phase chemopre-
vention trials.Page 2 of 2
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